EA025356B1 - Антагонисты trpm8 - Google Patents

Антагонисты trpm8 Download PDF

Info

Publication number
EA025356B1
EA025356B1 EA201491213A EA201491213A EA025356B1 EA 025356 B1 EA025356 B1 EA 025356B1 EA 201491213 A EA201491213 A EA 201491213A EA 201491213 A EA201491213 A EA 201491213A EA 025356 B1 EA025356 B1 EA 025356B1
Authority
EA
Eurasian Patent Office
Prior art keywords
thiazole
carboxylate
ethyl
oxy
fluorophenyl
Prior art date
Application number
EA201491213A
Other languages
English (en)
Russian (ru)
Other versions
EA201491213A1 (ru
Inventor
Алессио Морикони
Джанлука Бьянкини
Сандро Коладжоя
Лаура Брандолини
Андреа Арамини
Кьяра Либерати
Сильвия Боволента
Original Assignee
Домпе Фармачеутичи С.П.А
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11194365.0A external-priority patent/EP2606888A1/en
Application filed by Домпе Фармачеутичи С.П.А filed Critical Домпе Фармачеутичи С.П.А
Publication of EA201491213A1 publication Critical patent/EA201491213A1/ru
Publication of EA025356B1 publication Critical patent/EA025356B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/40—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/42—One oxygen atom attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201491213A 2011-12-19 2012-12-19 Антагонисты trpm8 EA025356B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11194365.0A EP2606888A1 (en) 2011-12-19 2011-12-19 Trpm8 antagonists
EP12178327 2012-07-27
PCT/EP2012/076147 WO2013092711A1 (en) 2011-12-19 2012-12-19 Trpm8 antagonists

Publications (2)

Publication Number Publication Date
EA201491213A1 EA201491213A1 (ru) 2014-11-28
EA025356B1 true EA025356B1 (ru) 2016-12-30

Family

ID=47520061

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491213A EA025356B1 (ru) 2011-12-19 2012-12-19 Антагонисты trpm8

Country Status (22)

Country Link
US (2) US9585875B2 (enExample)
EP (1) EP2793883B1 (enExample)
JP (2) JP6238906B2 (enExample)
KR (1) KR102000319B1 (enExample)
CN (1) CN104220069B (enExample)
AU (1) AU2012357747B2 (enExample)
CY (1) CY1120403T1 (enExample)
DK (1) DK2793883T3 (enExample)
EA (1) EA025356B1 (enExample)
ES (1) ES2676884T3 (enExample)
HR (1) HRP20181086T1 (enExample)
HU (1) HUE038407T2 (enExample)
LT (1) LT2793883T (enExample)
ME (1) ME03038B (enExample)
PL (1) PL2793883T3 (enExample)
PT (1) PT2793883T (enExample)
RS (1) RS57389B1 (enExample)
SI (1) SI2793883T1 (enExample)
SM (1) SMT201800351T1 (enExample)
TR (1) TR201808861T4 (enExample)
WO (1) WO2013092711A1 (enExample)
ZA (1) ZA201404499B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481727A1 (en) * 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
SMT201800351T1 (it) 2011-12-19 2018-09-13 Dompe Farm Spa Antagonisti trpm8
CA2908365C (en) 2013-05-24 2023-02-28 Nestec S.A. Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using linalool
US10294243B2 (en) 2014-06-05 2019-05-21 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pesticides
SI3157918T1 (sl) 2014-06-23 2019-05-31 Dompe Farmaceutici S.P.A. 2-aril-4-hidroksi-1,3-tiazolni derivati, uporabni kot inhibitorji TRPM8 pri zdravljenju nevralgije, bolečine, KOPB in astme
JP6865743B2 (ja) 2015-10-01 2021-04-28 フィルメニッヒ インコーポレイテッドＦｉｒｍｅｎｉｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｔｒｐｍ８の活性調節因子として有用な化合物
EP3184524A1 (en) * 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
JP6943887B2 (ja) 2016-06-13 2021-10-06 田辺三菱製薬株式会社 血管運動症状を治療または予防するための組成物および方法
WO2018117166A1 (ja) * 2016-12-21 2018-06-28 キッセイ薬品工業株式会社 チアゾール誘導体、またはその薬理学的に許容される塩

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153607A (en) * 1977-03-28 1979-05-08 Basf Aktiengesellschaft Process for the production of 4,5-disubstituted thiazoles
US5614520A (en) * 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
EP1321463A1 (en) * 2001-12-21 2003-06-25 Shire Biochem Inc. Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
US20100160289A1 (en) * 2008-12-18 2010-06-24 Macielag Mark J Sulfonamides as trpm8 modulators
WO2010125831A1 (en) * 2009-05-01 2010-11-04 Raqualia Pharma Inc. Sulfamoyl benzoic acid derivatives as trpm8 antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59220687A (ja) * 1983-05-30 1984-12-12 株式会社日立製作所 直接サイクル型軽水原子炉一次冷却系の腐食環境抑制設備
US20080214654A1 (en) 2004-10-13 2008-09-04 Bayer Healthcare Ag Substituted Benzyloxy-Phenylmethylamide Derivatives
WO2007017094A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted benzyloxy-phenylmethylcarbamate derivatives
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
WO2007080109A1 (en) 2006-01-16 2007-07-19 Bayer Healthcare Ag Substituded benzyloxy-phenylmethylurea derivatives
WO2007089031A1 (en) * 2006-02-01 2007-08-09 Takeda Pharmaceutical Company Limited Piperidine derivatives as tachykinin receptor antagonists
CA2651865C (en) 2006-05-10 2015-11-24 Janssen Pharmaceutica N.V. Cold menthol receptor-1 antagonists
EP2183239B1 (en) 2007-07-18 2012-08-22 Janssen Pharmaceutica, N.V. Sulfonamides as trpm8 modulators
WO2010103381A1 (en) 2009-03-13 2010-09-16 Glenmark Pharmaceuticals S.A. Spirocyclic piperidine derivatives as trpm 8 modulators
WO2012036233A1 (ja) * 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
SMT201800351T1 (it) 2011-12-19 2018-09-13 Dompe Farm Spa Antagonisti trpm8

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153607A (en) * 1977-03-28 1979-05-08 Basf Aktiengesellschaft Process for the production of 4,5-disubstituted thiazoles
US5614520A (en) * 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
EP1321463A1 (en) * 2001-12-21 2003-06-25 Shire Biochem Inc. Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
US20100160289A1 (en) * 2008-12-18 2010-06-24 Macielag Mark J Sulfonamides as trpm8 modulators
WO2010125831A1 (en) * 2009-05-01 2010-11-04 Raqualia Pharma Inc. Sulfamoyl benzoic acid derivatives as trpm8 antagonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BELLUS D. (ED.).: "SCIENCE OF SYNTHESIS. CATEGORY 2 : HETARENES AND RELATED RING SYSTEMS, FIVE-MEMBERED HETARENES WITH ONE CHALCOGEN AND ONE ADDITIONAL HETEROATOM.", 1 January 2002, STUTTGART : GEORG THIEME VERLAG., DE, ISBN: 978-3-13-112261-2, article BOYD G V: "PRODUCT CLASS 12: OXAZOLES", pages: 383 - 479, XP001156115, 027044 *
DRIDI K, ET AL.: "REACTION OF MERCAPTOACETATE AND HALIDES CONTAINING ACTIVATED METHYLENES WITH THIOCARBAMOYLIMIDATES: A NOVEL APPROACH TO THE SYNTHESIS OF AMINOTHIAZOLE DERIVATIVES", SYNTHETIC COMMUNICATIONS, TAYLOR & FRANCIS INC., PHILADELPHIA, PA; US, vol. 01, no. 28, 1 January 1998 (1998-01-01), PHILADELPHIA, PA; US, pages 167 - 174, XP008005382, ISSN: 0039-7911, DOI: 10.1080/00397919808005086 *
FRANCIS A. J. KERDESKY ET AL.: "4-Hydroxythiazole inhibitors of 5-Lipoxygenase", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 34, no. 7, 1 January 1991 (1991-01-01), US, pages 2158 - 2165, XP002423682, ISSN: 0022-2623, DOI: 10.1021/jm00111a035 *
HERTZOG, D.L. ; AL-BARAZANJI, K.A. ; BIGHAM, E.C. ; BISHOP, M.J. ; BRITT, C.S. ; CARLTON, D.L. ; COOPER, J.P. ; DANIELS, A.J. ; GA: "The discovery and optimization of pyrimidinone-containing MCH R1 antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 18, 15 September 2006 (2006-09-15), AMSTERDAM, NL, pages 4723 - 4727, XP025107256, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2006.07.008 *
ILYIN, A.P. ; PARCHINSKI, V.Z. ; PEREGUDOVA, J.N. ; TRIFILENKOV, A.S. ; POUTSYKINA, E.B. ; TKACHENKO, S.E. ; KRAVCHENKO, D.V. ; IV: "One-step assembly of carbamoyl substituted annulated 1,4-oxazepines", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 47, no. 15, 10 April 2006 (2006-04-10), AMSTERDAM, NL, pages 2649 - 2653, XP025003908, ISSN: 0040-4039, DOI: 10.1016/j.tetlet.2006.01.158 *
O TSUGE: "Studies of acyl and thioacyl isocyanates—XII The reactions of benzoyl and thiobenzoyl isocyanates with sulfonium ylides and with diazoalkanes", TETRAHEDRON, PERGAMON PRESS., vol. 29, no. 14, 1 January 1973 (1973-01-01), pages 1983 - 1990, XP055026677, ISSN: 00404020, DOI: 10.1016/0040-4020(73)80134-6 *
RONKIN, S.M. ; BADIA, M. ; BELLON, S. ; GRILLOT, A.L. ; GROSS, C.H. ; GROSSMAN, T.H. ; MANI, N. ; PARSONS, J.D. ; STAMOS, D. ; TRU: "Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 9, 1 May 2010 (2010-05-01), AMSTERDAM, NL, pages 2828 - 2831, XP027012843, ISSN: 0960-894X *

Also Published As

Publication number Publication date
AU2012357747A2 (en) 2014-08-21
PL2793883T3 (pl) 2018-09-28
HUE038407T2 (hu) 2018-10-29
US9856246B2 (en) 2018-01-02
RS57389B1 (sr) 2018-09-28
DK2793883T3 (en) 2018-07-30
WO2013092711A1 (en) 2013-06-27
EA201491213A1 (ru) 2014-11-28
SI2793883T1 (en) 2018-08-31
LT2793883T (lt) 2018-08-10
ZA201404499B (en) 2015-12-23
HRP20181086T1 (hr) 2018-09-07
KR102000319B1 (ko) 2019-09-27
EP2793883B1 (en) 2018-04-18
EP2793883A1 (en) 2014-10-29
JP2017197564A (ja) 2017-11-02
AU2012357747B2 (en) 2017-09-07
US9585875B2 (en) 2017-03-07
ME03038B (me) 2018-10-20
TR201808861T4 (tr) 2018-07-23
JP2015504874A (ja) 2015-02-16
PT2793883T (pt) 2018-07-18
US20140371276A1 (en) 2014-12-18
KR20150000870A (ko) 2015-01-05
AU2012357747A8 (en) 2014-07-24
HK1203810A1 (en) 2015-11-06
CN104220069A (zh) 2014-12-17
CN104220069B (zh) 2018-10-02
SMT201800351T1 (it) 2018-09-13
CY1120403T1 (el) 2019-07-10
AU2012357747A1 (en) 2014-07-10
US20170129881A1 (en) 2017-05-11
ES2676884T3 (es) 2018-07-25
JP6238906B2 (ja) 2017-11-29

Similar Documents

Publication Publication Date Title
EA025356B1 (ru) Антагонисты trpm8
AU2007248341B2 (en) Benzimidazole modulators of VR1
JP2012532914A (ja) テトラゾール誘導体
US11046662B2 (en) 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma
RS58809B1 (sr) Derivat 2-acilaminotiazola za upotrebu u prevenciji ili lečenju oboljenja bešike/urinarnog trakta
EP2606888A1 (en) Trpm8 antagonists
HK1235778A1 (en) 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and asthma
HK1235778B (en) 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and asthma
HK1203810B (zh) Trpm8拮抗剂
JP2018538334A (ja) Ｔｒｐｍ８拮抗薬としての４−ヒドロキシ−２−フェニル−１，３−チアゾール−５−イルメタノン誘導体
NZ715751B2 (en) Sulfonamides as modulators of sodium channels
NZ715751A (en) Sulfonamides as modulators of sodium channels